{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:51:25Z","timestamp":1787014285300,"version":"build-2736575974"},"reference-count":38,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T00:00:00Z","timestamp":1644278400000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The purpose of this study was to examine changes in the functional impact of migraine following treatment with erenumab, as measured by the Migraine Functional Impact Questionnaire (MFIQ).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The MFIQ, a novel patient\u2010reported outcome (PRO) measuring the impact of migraine on four domains (physical function, social function, and emotional function [PF, SF, and EF]; usual activities [UAs]) and a single item assessing overall impact on UA, was included in phase III trials evaluating erenumab 70 and 140\u00a0mg monthly for migraine prevention among people with episodic migraine (EM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In the ARISE study, 577 patients with EM were randomized to erenumab 70\u00a0mg or placebo. In the STRIVE study, 955 patients with EM were randomized to erenumab, 70\u00a0mg or 140\u00a0mg or placebo. Pairwise comparisons of least\u2010squares mean (LSM) change from baseline in MFIQ scores (with associated 95% confidence interval [CI]) were assessed for each active treatment versus placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In ARISE, greater reductions from baseline to month 3 were observed for 70\u00a0mg versus placebo for PF (LSM [95% CI]: \u22123.2 [\u22126.4 to \u22120.1];\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.046) and EF (\u22124.0 [\u22127.3 to \u22120.7];\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.019) domain scores. In STRIVE, between\u2010group differences also reflected reductions from baseline to the average of months 4\u20136 that favored erenumab on all four MFIQ domain scores. Reductions in impact for 70\u00a0mg compared to placebo were \u22124.3 (95% CI: \u22126.8 to \u22121.7;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.001) for PF, \u22124.0 (\u22126.3 to \u22121.7;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.001) for UA, \u22123.7 (\u22126.1 to \u22121.2;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.003) for SF, and \u22125.3 (\u22127.9 to \u22122.6;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.001) for EF domain scores. Improvements were also observed for 140\u00a0mg versus placebo with between\u2010group differences of \u22125.7 (95% CI: \u22128.2 to \u22123.2;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.001) in PF, \u22125.1 (\u22127.5 to \u22122.8;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.001) in UA, \u22125.0 (\u22127.4 to \u22122.6;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.001) in SF, and \u22127.2 (\u22129.9 to \u22124.5;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.001) in EF domain scores. There were also greater improvements in the overall impact on UA score for 70\u00a0mg (LSM [95% CI]: \u22124.3 [\u22127.0 to \u22121.7];\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.001) and 140\u00a0mg (\u22125.3 [\u22128.5 to \u22123.2];\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.001) versus placebo.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The MFIQ measures the frequency of impacts and level of difficulty on multiple functional domains that provide a more complete picture of the effects of migraine. MFIQ scores showed that in comparison with placebo, patients treated with erenumab had greater reductions in the functional impact of migraine, providing insight into treatment benefits that extend beyond improvements in clinical status and health\u2010related quality of life previously reported based on clinical end points and other PROs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.14258","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T01:34:08Z","timestamp":1644370448000},"page":"159-168","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Reducing the physical, social, and emotional impact of episodic migraine: Results from erenumab STRIVE and ARISE phase III randomized trials"],"prefix":"10.1111","volume":"62","author":[{"given":"Ariane K.","family":"Kawata","sequence":"first","affiliation":[{"name":"Evidera Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Kate","family":"Ladd","sequence":"additional","affiliation":[{"name":"Evidera Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Lipton","sequence":"additional","affiliation":[{"name":"Department of Neurology Albert Einstein College of Medicine New York New York USA"},{"name":"Department of Neurology Montefiore Medical Center New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn C.","family":"Buse","sequence":"additional","affiliation":[{"name":"Department of Neurology Albert Einstein College of Medicine New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bensink","sequence":"additional","affiliation":[{"name":"Global Health Economics Amgen Inc. Thousand Oaks California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shweta","family":"Shah","sequence":"additional","affiliation":[{"name":"Global Health Economics Amgen Inc. Thousand Oaks California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asha","family":"Hareendran","sequence":"additional","affiliation":[{"name":"Evidera London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Mannix","sequence":"additional","affiliation":[{"name":"Evidera Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Mikol","sequence":"additional","affiliation":[{"name":"Global Development Amgen Inc. Thousand Oaks California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,2,8]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2007.01288.x"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-016-0542-3"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)60561-2"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-016-0599-8"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13420"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182535d20"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1212\/CON.0000000000000199"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70005-3"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13202"},{"key":"e_1_2_10_11_1","doi-asserted-by":"crossref","first-page":"929","DOI":"10.2146\/news180044","article-title":"FDA approves licensing of erenumab\u2010aooe to prevent migraine","volume":"75","author":"Traynor K","year":"2018","journal-title":"Am J Health Syst Pharm"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1004-5"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1002-7"},{"key":"e_1_2_10_14_1","volume-title":"Eptinezumab Approved for Migraine Prevention","author":"Hoffman M","year":"2020"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.115.227793"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705848"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418759786"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007452"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418758283"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420941839"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13456"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13569"},{"key":"e_1_2_10_23_1","first-page":"65132","article-title":"Guidance for industry on patient\u2010reported outcome measures: use in medical product development to support labeling claims","volume":"74","author":"Food and Drug Administration","year":"2009","journal-title":"Fed Reg"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.06.013"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.06.014"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-017-0799-1"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13162"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14069"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079901753403207"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026119331193"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.suppl_1.S20"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199813060-00007"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2008.01.026"},{"key":"e_1_2_10_34_1","volume-title":"International Classification of Functioning. Disability and Health. ICF","author":"World Health Organization","year":"2001"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418789072"},{"key":"e_1_2_10_36_1","first-page":"113","article-title":"Patient\u2010reported outcomes from the ARISE trial: a phase 3, randomized, double\u2010blind study of erenumab in subjects with episodic migraine (abstract P22)","volume":"57","author":"Ashina M","year":"2017","journal-title":"Headache"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14053"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2001.111006343.x"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-008-0591-3"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14258","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/head.14258","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14258","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:37:13Z","timestamp":1762079833000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.14258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1111\/head.14258"],"URL":"https:\/\/doi.org\/10.1111\/head.14258","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"2021-02-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}